Congress is considering a new bill that, in theory, would boost low-income patients’ - especially Latinos’ - access to ...

The 340B Drug Pricing Program (340B program) is a federal drug discount program that requires drug manufacturers participating in the Medicaid drug rebate program to provide outpatient drugs to ...

Spending through the 340B Drug Pricing Program rose by 565% between 2010 and 2021, increasing from $6.6 billion to $43.9 billion, according to a report from the Congressional Budget Office. In 2021, ...

Republican lawmakers in the House have introduced a bill Tuesday that tightens eligibility and public reporting requirements within the 340B Drug Discount Program, earning the applause of industry ...

Hospitals are up in arms over new guidance issued by the Health Resources and Services Administration on Thursday that could restrict the eligibility of their outpatient clinics for drug discounts in ...

A bipartisan group of 163 lawmakers is urging the Department of Health and Human Services (HHS) to cancel an upcoming pilot ...

The 100% woman-owned consulting firm partners with healthcare organizations to help them understand, implement, and optimize ...

The results indicate that the program could play a role in discouraging use of biosimilars in the United States. Hospitals participating in the 340B Drug Pricing Program had lower biosimilar uptake, ...

The hospital lobby wants the Trump administration to investigate Johnson & Johnson, Eli Lilly, Sanofi, Novartis and Bristol ...